[Therapeutic strategy for acute rejection in organ transplantation--optimal use of monoclonal antibody].
Transplantation has now become the treatment of choice for end-stage organ failure. However, acute rejection still occurs in approximately 20-50% of cadaver or living donor kidney recipients during the first year post-transplantation and lead to permanent damage of graft function or loss. Recently chimeric(basiliximab) and the humanized(daclizumab) monoclonal antibodies against the alpha chain(CD25) of the interleukin 2 receptor(IL-2R) introduced in the late 1990s. Induction therapy with these antibodies results in a 15-20% reduction in acute rejection episodes after renal transplantation. The availability of anti-IL-2R monoclonal antibodies offers a further opportunity for graft-specific induction therapy.
Hanafusa
Toru
T
Department of Urology, Osaka University Graduate School of Medicine.
Takahara
Shiro
S
D000208:Acute Disease; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077552:Basiliximab; D002986:Clinical Trials as Topic; D000077561:Daclizumab; D006084:Graft Rejection / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D051379:Mice; D016377:Organ Transplantation; D015375:Receptors, Interleukin-2 / Q000276:immunology; D011993:Recombinant Fusion Proteins; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000077561:Daclizumab